



EMVision Medical Devices Ltd
ACN 620 388 230
Suite 4.01, 65 Epping Rd
Sydney NSW 2113
02 8667 5337
contact@emvision.com.au

ASX Release

\$3.8M R&D REBATE RECEIVED & ADVANCE OVERSEAS FINDING APPROVED

EMVision Medical Devices Limited (ASX:EMV) (“EMVision” or the “Company”) is pleased to advise that it has received a \$3.8 million R&D tax refund in relation to eligible R&D activities undertaken by the Company in the financial year ended 30 June 2025.

The Company is also pleased to confirm that AusIndustry has approved its Advance Overseas Finding application, covering eligible overseas expenditure associated with the emu™ pivotal (validation) trial and related market access activities. This includes US-based CRO and hospital site costs, as well as supporting administration, professional advisory and regulatory expenses.

This approval is an important outcome for EMVision, enabling the Company to access the Australian Government’s cash R&D tax rebate, currently 43.5%, on eligible overseas R&D expenditure for these activities across the 2025, 2026 and 2027 financial years.

Together, the \$3.8 million refund and the approved overseas finding strengthens EMVision’s funding position as the Company advances the emu™ pivotal (validation) trial and associated market access initiatives.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Emma Waldon
Company Secretary
+61 2 8667 5337
ewaldon@emvision.com.au

Scott Kirkland
CEO and Managing Director
+61 2 8667 5337
skirkland@emvision.com.au

For personal use only

About EMVision Medical Devices

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neurodiagnostic devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.